72,000 Shares in Cencora, Inc. $COR Acquired by Employees Provident Fund Board

Employees Provident Fund Board purchased a new stake in Cencora, Inc. (NYSE:COR) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 72,000 shares of the company’s stock, valued at approximately $24,318,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Reflection Asset Management purchased a new position in Cencora during the fourth quarter worth approximately $59,000. BDFS Capital LLC purchased a new position in shares of Cencora in the fourth quarter valued at $831,000. Tempo Wealth LLC acquired a new position in shares of Cencora in the 4th quarter valued at approximately $575,000. MidFirst Bank acquired a new stake in Cencora in the fourth quarter valued at $424,000. Finally, DGS Capital Management LLC increased its holdings in Cencora by 12.8% in the fourth quarter. DGS Capital Management LLC now owns 1,395 shares of the company’s stock valued at $471,000 after buying an additional 158 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 0.1%

COR opened at $271.99 on Friday. The company has a market capitalization of $52.92 billion, a P/E ratio of 20.86, a P/E/G ratio of 1.47 and a beta of 0.59. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The firm’s fifty day moving average price is $284.59 and its two-hundred day moving average price is $324.35.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. During the same period in the prior year, the business earned $4.42 earnings per share. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora declared that its board has authorized a stock repurchase program on Thursday, May 21st that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to repurchase up to 3.9% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were issued a dividend of $0.60 per share. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. Cencora’s dividend payout ratio (DPR) is 18.40%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on COR. UBS Group raised their target price on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Wells Fargo & Company cut their price target on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a report on Monday, May 11th. Evercore set a $360.00 target price on Cencora in a report on Wednesday, April 8th. Weiss Ratings lowered Cencora from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 22nd. Finally, Citigroup cut their price objective on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $374.00.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.